このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Guizhou Sanli PharmaceuticalLtd マネジメント

マネジメント基準チェック /34

Guizhou Sanli PharmaceuticalLtd'sの CEO はHai Zhangで、 Jan2015年に任命され、の在任期間は 9.42年です。は、会社の株式の51.93%を直接所有しており、その価値はCN¥ 3.01B 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と4.7年です。

主要情報

Hai Zhang

最高経営責任者

CN¥757.1k

報酬総額

CEO給与比率	n/a
CEO在任期間	9.4yrs
CEOの所有権	51.9%
経営陣の平均在職期間	4.8yrs
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Apr 23

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 06

CEO（最高経営責任者

Hai Zhang (38 yo)

9.4yrs

在職期間

CN¥757,100

報酬

Mr. Hai Zhang is Chairman & GM of Guizhou Sanli Pharmaceutical Co.,Ltd from January 2015.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Hai Zhang	Chairman & GM	9.4yrs	CN¥757.10k	51.93% CN¥ 2.7b
Hongyu Zhang	CFO & Director	9.4yrs	CN¥474.80k	0.064% CN¥ 3.3m
Jing Long	Chairman of the Supervisory Board & Manager of Human Resources Department	3.1yrs	CN¥314.20k	0.0038% CN¥ 197.4k
Yuan Yu	Deputy General Manager	3.1yrs	CN¥534.60k	0.018% CN¥ 956.9k
Yi Wang	Deputy General Manager	6.3yrs	CN¥546.20k	0.23% CN¥ 11.9m
Ke Guo	Deputy General Manager	3.4yrs	CN¥533.20k	0.059% CN¥ 3.1m
Donghai Liang	Supervisor & Business Manager	1.6yrs	CN¥300.30k	0.0038% CN¥ 197.4k
Qianfan Zhang	Vice Chairman & Board Secretary	6.3yrs	CN¥536.90k	0.11% CN¥ 5.9m

4.8yrs

平均在職期間

38.5yo

平均年齢

経験豊富な経営陣: 603439の経営陣は経験豊富であると考えられます ( 4.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Hai Zhang	Chairman & GM	9.4yrs	CN¥757.10k	51.93% CN¥ 2.7b
Hongyu Zhang	CFO & Director	9.4yrs	CN¥474.80k	0.064% CN¥ 3.3m
Jing Long	Chairman of the Supervisory Board & Manager of Human Resources Department	3.1yrs	CN¥314.20k	0.0038% CN¥ 197.4k
Donghai Liang	Supervisor & Business Manager	1.6yrs	CN¥300.30k	0.0038% CN¥ 197.4k
Qianfan Zhang	Vice Chairman & Board Secretary	6.3yrs	CN¥536.90k	0.11% CN¥ 5.9m
Yongjian Sheng	Director	9.4yrs	データなし	5.37% CN¥ 279.8m
Shi Gui Chen	Independent Director	1.5yrs	データなし	データなし
Wang Qiang	Independent Director	1.5yrs	データなし	データなし

4.7yrs

平均在職期間

45yo

平均年齢

経験豊富なボード: 603439の取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

Guizhou Sanli PharmaceuticalLtd マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Guizhou Sanli Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Recent updates

Guizhou Sanli Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 29, 2024

Guizhou Sanli Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 1Q 2023)

Now 20% overvalued

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 22% undervalued

Now 21% undervalued

Now 20% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.089 in 3Q 2022)

Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.089 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 2Q 2021)

GuiZhou SanLi Pharmaceutical Co.,Ltd (SHSE:603439) signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.06 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GuiZhou SanLi Pharmaceutical Co., Ltd. (SHSE:603439) agreed to acquire 95% stake in Guiyang Dechang Xiang Pharmaceutical Co., Ltd from Guizhou Jingyi Garden Ecological Planting Co., Ltd. and Guiyang Dechang Xiang Pharmaceutical Co., Ltd.’s Trade Union Committee for CNY 230 million.

Now 21% undervalued

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.005 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.053 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.24 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.39

New 90-day low: CN¥18.03

New 90-day low: CN¥20.70

Third quarter earnings released

New 90-day low: CN¥23.10

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low - CN¥26.68

First half earnings released

First half earnings released

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report First Half, 2020 Results on Aug 28, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34